title: Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials.
abstract: Lopinavir/ritonavir (LPV/r) is the first ritonavir-boosted protease-inhibitor used in second-line anti-retroviral treatment (ART) in resource-limited regions. To evaluate the efficacy and safety outcomes of LPV/r in treatment-naïve and -experienced HIV-infected adults and pregnant women, we performed a meta-analysis of randomized controlled trials. Ten cohorts from 8 articles involving 2,584 ART-naïve patients, 5 cohorts from 4 articles involving 1,124 ART-experienced patients, and 8 cohorts from 7 articles involving 2,191 pregnant women were selected for the meta-analyses. For ART-naïve patients, the virologic response rate (72.3%) of LPV/r combined with tenofovir (TDF) plus lamivudine/emtricitabine (3TC/FTC) arms was significantly greater than that of LPV/r plus non-TDF-FTC arms (65.5%, p = 0.047). For ART-experienced patients, the use of LPV/r revealed a 55.7% probability of virologic success. The incidence of abnormal total cholesterol (6.9%) for ART-experienced patients was significantly lower than that for ART-naïve patients (13.1%, p < 0.001). The use of LPV/r in pregnant women revealed a mother-to-child transmission (MTCT) rate of 1.1%, preterm birth rate of 13.2%, and low birth weight rate of 16.2%. Our meta-analysis indicated that LPV/r was an efficacious regimen for ART-naïve patients and was more tolerable for ART-experienced patients. LPV/r also displayed a significant effect in preventing MTCT.
authors.affiliation: Center for Infectious Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China.
authors.forename: Xiaojie
authors.initials: X
authors.lastname: Huang
authors.affiliation: 1] Center for Infectious Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China [2] Guangxi Longtan Hospital, Liuzhou, Guangxi 545005, China.
authors.forename: Yuanlong
authors.initials: Y
authors.lastname: Xu
authors.affiliation: 1] School of Biomedical Engineering, Capital Medical University, Beijing 100069, China [2] Beijing Key Laboratory of Fundamental Research on Biomechanics in Clinical Application, Capital Medical University, Beijing 100069, China.
authors.forename: Qiuying
authors.initials: Q
authors.lastname: Yang
authors.affiliation: School of Biomedical Engineering, Capital Medical University, Beijing 100069, China.
authors.forename: Jieqing
authors.initials: J
authors.lastname: Chen
authors.affiliation: Center for Infectious Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China.
authors.forename: Tong
authors.initials: T
authors.lastname: Zhang
authors.affiliation: Center for Infectious Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China.
authors.forename: Zaicun
authors.initials: Z
authors.lastname: Li
authors.affiliation: Center for Infectious Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China.
authors.forename: Caiping
authors.initials: C
authors.lastname: Guo
authors.affiliation: 1] School of Biomedical Engineering, Capital Medical University, Beijing 100069, China [2] Beijing Key Laboratory of Fundamental Research on Biomechanics in Clinical Application, Capital Medical University, Beijing 100069, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Chen
authors.affiliation: Center for Infectious Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Wu
authors.affiliation: Center for Infectious Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China.
authors.forename: Ning
authors.initials: N
authors.lastname: Li
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D001724:Birth Weight; D002784:Cholesterol / Q000097:blood; D016208:Databases, Factual; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission; D006801:Humans; D007231:Infant, Newborn; D061466:Lopinavir / Q000627:therapeutic use*; D011247:Pregnancy; D047928:Premature Birth; D016032:Randomized Controlled Trials as Topic; D019438:Ritonavir / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D061466:Lopinavir; D002784:Cholesterol; D019438:Ritonavir